Definium Therapeutics’ (DFTX) “Overweight” Rating Reiterated at Piper Sandler

Дата публикации: 10-08-2026 05:48:47

Piper Sandler reiterated their overweight rating on shares of Definium Therapeutics (NASDAQ:DFTX – Free Report) in a research report released on Friday morning,Benzinga reports. They currently have a $75.00 price objective on the stock, up from their prior price objective of $73.00. Several other research analysts have also recently issued reports on the stock. Canaccord […]

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Teleflex’s (TFX) Overweight Rating Reiterated at Piper Sandler	0	10.31	10-08-2026
2	Doximity’s (DOCS) “Overweight” Rating Reiterated at Piper Sandler	0	9.98	10-08-2026
3	Sotera Health’s (SHC) Overweight Rating Reiterated at Piper Sandler	0	9.05	10-08-2026
4	Shoulder Innovations’ (SI) Overweight Rating Reiterated at Piper Sandler	0	8.45	10-08-2026
5	STERIS’s (STE) “Overweight” Rating Reiterated at Piper Sandler	0	9.98	10-08-2026
6	Somnigroup International’s (SGI) “Overweight” Rating Reiterated at Piper Sandler	0	9.05	10-08-2026
7	Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $175.00	0	12.26	10-08-2026
8	Collegium Pharmaceutical’s (COLL) “Neutral” Rating Reiterated at Piper Sandler	0	9.68	10-08-2026
9	Piper Sandler Cuts ResMed (NYSE:RMD) Price Target to $225.00	0	10.45	10-08-2026
10	Trulieve Cannabis’ (TRLV) Overweight Rating Reiterated at Cantor Fitzgerald	0	6.89	10-08-2026

Классификация: Экономика. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.75. Источник: www.americanbankingnews.com.